Frazier Life Sciences Management, L.P. Akero Therapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $2.36 Billion
- Q3 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 366,784 shares of AKRO stock, worth $19.9 Million. This represents 0.74% of its overall portfolio holdings.
Number of Shares
366,784
Previous 366,784
-0.0%
Holding current value
$19.9 Million
Previous $19.6 Million
11.02%
% of portfolio
0.74%
Previous 1.03%
Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
302Shares Held
91.5MCall Options Held
1.05MPut Options Held
388K-
Janus Henderson Group PLC London, X06.28MShares$340 Million0.14% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$311 Million9.63% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$303 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$297 Million3.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$245 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.52B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...